Trial · NCT07462988
Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain
NCT07462988, Not applicable, Completed, Istanbul Medeniyet University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain. Trials, record NCT07462988. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07462988
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain
- NCT number
- NCT07462988
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 80 participants, actual
- Lead sponsor
- Istanbul Medeniyet University
- Conditions
- Neck Pain, Mesotherapy
- Interventions
- Lidocaine %2 ampoule, Meloxicam ampoule, Saline (0.9% NaCl), Dry Needling
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analogue Scale (VAS) | Start, One month after the start, Three months after the start | The Visual Analogue Scale (VAS) is a simple, widely used tool for assessing pain intensity. It typically consists of a 10-cm horizontal line anchored by "no pain" on one end and "worst imaginable pain" on the other. Patients mark a point on the line that corresponds to their pain level, which is then measured in millimeters. Higher scores indicate greater pain intensity. Rest pain, activity-related pain, and night pain were assessed. |
| Secondary | Neck Disability Index (NDI) | Start, one month after the start, three months after the start | The Neck Disability Index (NDI) is a widely used self-report questionnaire that measures functional disability associated with neck pain. It consists of 10 items scored from 0 to 5, covering pain intensity and daily activities. Higher scores indicate greater disability. The NDI is commonly used in clinical practice and research to assess baseline status and monitor treatment outcomes. |
| Secondary | 12-Item Short Form Survey (SF-12) | Start, one month after the start, three months after the start | The 12-Item Short Form Survey (SF-12) is a brief, validated questionnaire used to assess overall health-related quality of life. It measures physical and mental health through 12 questions derived from the SF-36. The survey generates two main scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Higher scores indicate better health status. The SF-12 is widely used in clinical practice and research due to its brevity, reliability, and ability to capture general functional health. |
| Secondary | Pressure Pain Threshold (PPT) | Start, one month after the start, three months after the start | Pressure Pain Threshold (PPT) is a quantitative measure of pain sensitivity assessed using a pressure algometer. It represents the minimum amount of pressure that evokes pain. PPT is widely used in clinical and research settings to evaluate mechanical pain sensitivity, detect hyperalgesia, and monitor treatment effects. Lower PPT values indicate increased pain sensitivity, while higher values reflect reduced sensitivity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07462988
GET https://conductscience.org/api/trials/v1/NCT07462988/registered